[EN] TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION<br/>[FR] COMPOSÉS CONTENANT DES ACIDES AMINÉS TRICYCLIQUES POUR LE TRAITEMENT OU LA PRÉVENTION DE SYMPTÔMES ASSOCIÉS À UN DYSFONCTIONNEMENT ENDOCRINIEN
申请人:UNIV EMORY
公开号:WO2013070660A1
公开(公告)日:2013-05-16
The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.
本公开提供了使用某些化合物治疗内分泌紊乱的某些症状的方法,特别是与潮热相关的症状的方法。
Compositions cosmétique contenant une para-phénylènediamines doubles reliées par un groupe aromatique et utilisation en coloration
申请人:L'ORÉAL
公开号:EP1739085A1
公开(公告)日:2007-01-03
La présente demande concerne une nouvelle famille de para-phénylènediamines doubles reliées par un bras de liaison comportant un groupement aromatique et leur utilisation pour la coloration des fibres kératiniques.
Ces nouvelles para-phénylènediamines doubles de formule (I) sont utiles en tant que base d'oxydation pour la coloration des fibres kératiniques.
Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
申请人:Emory University
公开号:US10632120B2
公开(公告)日:2020-04-28
The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.
作者:Weiqiang Zhan、Zhongxing Liang、Aizhi Zhu、Serdar Kurtkaya、Hyunsuk Shim、James P. Snyder、Dennis C. Liotta
DOI:10.1021/jm070679i
日期:2007.11.1
In light of a proposed molecular mechanism for the C-X-C chemokine receptor type 4 (CXCR4) antagonist 1 (AMD3100), a template with the general structure 2 was designed, and 15 was identified as a lead by means of an affinity binding assay against the ligand-mimicking CXCR4 antagonist 3 (TN14003). Following a structure-activity profile around 15, the design and synthesis of a series of novel small molecular CXCR4 antagonists led to the discovery of 32 (WZ811). The compound shows subnanomolar potency (EC50 = 0.3 nM) in an affinity binding assay. In addition, when subjected to in vitro functional evaluation, 32 efficiently inhibits CXCR4/stromal cell-derived factor-1 (SDF-1)-mediated modulation of cyclic adenosine monophophate (CAMP) levels (EC50 = 1.2 nM) and SDF-1 induced Matrigel invasion (EC50 = 5.2 nM). Molecular field topology analysis (MFTA), a 2D quantitative structure-activity relationship (QSAR) approach based on local molecular properties (Van der Waals radii (VdW), atomic charges, and local lipophilicity), applied to the 32 series suggests structural modifications to improve potency.
TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION